Publications

  1. Pimentel M, Purdy C, Magar R, Rezaie A. A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. Clinical Therapeutics. 2016; 38(7):1638-1652
  2. McAndrew CP, Tyson C, Zischkau J, Mehl P, Tuma PL, Pegg IL, Sarkar A.Simple horizontal magnetic tweezers for micromanipulation of single DNA molecules and DNA–protein complexes. BioTechniques. 2016; 60(1):21–27
  3. Tyson C, McAndrew CP, Tuma PL, Pegg IL, Sarkar A. Automated Nonparametric Method for Detection of Step-Like Features in Biological Data Sets. Cytometry Part A. 2015; 87A:393-404.
  4. Purdy C, Bytzer PM, Pimentel M, Magar R. A novel IBS diagnostic blood panel can enhance a positive diagnostic strategy versus a strategy of exclusion for patients with diarrhea predominant irritable bowel syndrome (IBS-D): Cost implications for Denmark. Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
  5. Pimentel M, Purdy C, Magar R. Cost-minimization for a novel diagnostic blood panel versus standard exclusionary diagnostic testing for diarrhea predominant irritable bowel syndrome: A United States perspective. Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
  6. Schmulson MJ, Castillo Barradas M, Pimentel M, Magar R, Purdy C. Impact of a novel IBS diagnostic blood panel for Mexico: Cost implications to the Mexican private practice for diarrhea predominant irritable bowel syndrome (IBS-D). Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
  7. Soubieres A, Pimentel M, Purdy C, Magar R. Inclusion of a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): A UK perspective. Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
  8. Gabbani T, Violanti C, Deiana S, Pimentel M, Purdy C, Magar R. Potential for cost savings associated with a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): Italian perspective. Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
  9. Reddy A, Policastro A, Reppine A, Sekab J, Purdy C, Dalfonso L, Magar R. Assessing Migraine: An Enquiry into Prophylactic Treatment Patterns by Diagnosis: The AMEND Study. Presented at American Academy of Neurology Annual Meeting, Washington, DC. 2015.
  10. Gupta A, Lehman H, Dalfonso L, Gressani C, Purdy C, Wetzel L, Magar R. A Prospective Pilot Study Evaluating the HRQOL Impact of a Novel Air Purification Technology for Pediatric Asthma Patients. Presented at ISPOR Annual International Meeting, Montreal, QC, CA. 2014.
  11. Blumenfeld A, Inocelda A, Cunanan C, Purdy C, Dalfonso L, Magar R. The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study. Presented at American Academy of Neurology Annual Meeting, Philadelphia, PA. 2014.
  12. Tzoulis C, Kent R, Robertson A, Maltman J, Purdy C, Magar R. The Retrospective Evaluation of the Dose of IncobotulinumtoxinA and OnabotulinumtoxinA for the Clinical Management of Cervical Dystonia and Blepharospasm: TRUDOSE Pilot Study. Presented at American Academy of Neurology Annual Meeting, Philadelphia, PA. 2014.
  13. Blumenfeld A, Inocelda A, Cunanan C, Purdy C, Dalfonso L, Magar R. Long-term treatment of chronic migraine with onabotulinumtoxinA: CLARITY pilot study. Presented at the 33rd Annual Scientific Meeting of the American Pain Society, Tampa, FL. 2014.
  14. Gärtner M, Petzel M, Kublanck A, Eckert R, Schmidtke M, Purdy C, Magar R, Dalfonso L, Walters C. A Non-interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real World Evaluation (The REDUCE Study - Interim Analysis). Presented at the International Continence Society Annual Meeting, Barcelona, Spain. 2013.
  15. Indig M, Purdy C, Magar R, Dalfonso L, Walters C, Nazir J. A Non-Interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real Worl Evaluation: German Perspective (The REDUCE Study). Presented at ISPOR 16th Annual European Congress, Dublin, Ireland. 2013.
  16. Wexner SD, Bernstein M, Purdy C, Magar R. A five-year Markov model evaluating the cost-utility of NASHA/DX for the treatment of fecal incontinence: A United States perspective. Presented at ISPOR 15th Annual European Congress, Berlin, DE. 2012.
  17. Pimentel M, Schoenfeld P, Purdy CH, Gilbert C, Magar RCost Savings Associated With Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome. American Journal of Pharmacy Benefits. 2012;4(3):e65-e72.
  18. Yoelin S, Caulkins C, Magar R, Purdy C, Dalfonso L. Interim Analysis of A Non-Interventional Observational And Medical Records Review of Patient Outcomes With Bimatoprost Ophthalmic Solution 0.03% for The Treatment of Hypotrichosis of The Eyelashes. Presented at World Congress of Dermatology, Seoul, Korea. 2011.
  19. Santos-Oliveira R, Purdy C, da Silva MP, Dos Anjos Carneiro-Leão AM, Machado M, Einarson TR. Haemoglobin A(1c) levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia. 2011; 54(6):1327-34.
  20. Henderson D, Purdy C, Magar RM, Hayward AH. The Potential Economic Benefits Provided By Combining Cisplatin with Src Inhibitor Kx1-004 for Cancer Regimens. Presented at ISPOR 15th Annual International Meeting, Atlanta, GA. 2010.
  21. Czyrny JJ, Kaplan RE, Wilding GE, Purdy CH, and Hirsh J. Electrical Foot Stimulation: A Potential New Method of Deep Venous Thrombosis Prophylaxis. Vascular. 2010; 18(1):20-27.
  22. Canfield M, Keller C, Frydrych L, Ashrafioun L, Purdy C, Blondell R. Prescription Opioid Use Among Patients Seeking Treatment for Opioid Dependence. J Addict Med. 2010; 4:108-113.
  23. Magar R, Purdy C, Hayward AH, Einarson TR, Burnett AK. Cost-effectiveness Analysis of Histamine Dihydrochloride + Low Dose Interleukin-2 Vs Standard of Care for Remission Maintenance for Acute Myeloid Leukemia Patients in their First Complete Remission: A UK Perspective. Presented at ISPOR 12th Annual European Meeting, Paris, France. 2009.
  24. Purdy CH, Magar RS, Hayward A, Einarson TR. Comparison of Two Methods to Determine Costs for AML Patients in Remission Maintenance: Model Validation from a UK Perspective. Presented at ISPOR 12th Annual European Meeting, Paris, France. 2009.
  25. Hayward AH, Purdy CH, Hargrave B, Voltz C, Magar R. AIDS Community Services of Western New York: A Comprehensive Model for HIV Care and Prevention. Presented at ISPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI. 2009.
  26. Frydrych LM, Greene BJ, Blondell RD, Purdy CH. Self-Help Components and Linkage to Aftercare Following Inpatient Detoxification. J Addict Dis. 2009. 28(1).
  27. Hayward AH, Purdy CH, Magar R, Iskedjian MI. Incremental Cost Savings Associated with Bariatric Surgery in WNY. Presented at the 11th Annual ISPOR Meeting, Greece. November (2008).
  28. Hayward AH, Purdy CH, Magar R, Iskedjian MI. The Impact of Bariatric Surgery on Psychological Parameters . DIA, Boston, June (2008).
  29. Hayward AH, Purdy CH, et al. The Development of a Standardized Clinical Algorithmic Predictor of Weight Loss After Bariatric Surgery: Database Analysis Enables Empirical and Statistical Prediction of Threshold Weight Loss by End of Third Post-Operative Visit. Presented at the 11th Annual ISPOR Meeting, Toronto, May (2008).
  30. Wisniewski A, Purdy CH, et al. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis. 2008. 27(1): 1-11.
  31. Magar RS, Fine PG, White RE.Expected Cost and Cost Considerations Associated with Opioid Rotation for Chronic Non-Cancer Pain: A Simulation Model. Presented at 10th Annual ISPOR Meeting, Dublin, Ireland (2007).
  32. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F. Retrospective Evaluation of the Dose of Dysport® and BOTOX® in the Management of Cervical Dystonia and Blepharospasm: The REAL DOSE Study. Movement Disorders, Apr 2005, 20 (8) p937 – 944
  33. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002:24; 378-396.
  34. Marchetti A, Magar R, Lau H. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther, Nov 2001, 23(11) p1904-21.
  35. Marchetti A, Magar R, An P. Clinical and economic impact of new trends in glaucoma treatment. MedGenMed, Jul 26 2001, 3(4) p6
  36. Brashear A, Watts MW, Marchetti A, Magar R. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther, Dec 2000, 22(12) p1516-24.
  37. Marchetti A, Wang L, Magar R. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther, Apr 2000, 22(4) p422-38.
  38. Marchetti A, Magar R, Lau H. RSV Hospitalization Charges for Infants not Prophylaxed and Prophylaxed with Palivizumab. Presented at AAP Annual Meeting Critical Care, Emergency Medicine & Transport Medicine, Boston, MA (2000).
  39. Marchetti A, Lau H, Magar R. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther, Apr 1999, 21(4) p752-66.
  40. Marchetti A, Magar R, Fischer J. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther, Sep-Oct 1996, 18(5) p953-66.
  41. Magar RS, Doucette D, Kassam R, Seto W, Einarson TR. Warfarin in atrial fibrillation: a meta-analysis and Pharmacoeconomic analysis. Canadian Journal of Clinical Pharmacology. 1995; 2:109-17.